The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice

Diabetologia

Volumn 46, Issue 1, 2003, Pages 71-79

  Vidal, J ^a,b   Verchere, C Bruce ^a,b   Andrikopoulos, S ^a,b   Wang, F ^a,b   Hull, R L ^a,b   Cnop, M ^a,b   Olin, K L ^a   LeBoeuf, R C ^a   O'Brien, K D ^c   Chait, A ^a   Kahn, S E ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amylin; Apolipoprotein E; Diabetes; Islet amyloid; Islet amyloid polypeptide

Indexed keywords

AMYLIN; AMYLOID; APOLIPOPROTEIN E; IMMUNOREACTIVE INSULIN; LIPID;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS BREEDING; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; IN VIVO STUDY; LIPID BLOOD LEVEL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; TRANSGENIC MOUSE; TREATMENT INDICATION;

EID: 0037281013     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0984-5     Document Type: Article

References (43)

1. Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253
2. Kisilevsky R (1998) Amyloid beta threads in the fabric of Alzheimer's disease. Nat Med 4:772-773
3. Westermark P (1972) Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77:91-94
4. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH (1987) Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 127:414-417
5. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628-8632
6. Clark A, Saad MF, Nezzer T et al. (1990) Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285-289
7. D'Alessio DA, Verchere CB, Kahn SE et al. (1994) Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457-1461
8. Fox N, Schrementi J, Nishi M et al. 1993 Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NDDM). FEBS Lett 323:40-44
9. Couce M, Kane LA, O'Brien TD et al. (1996) Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes 45:1094-1101
10. Höppener JW, Oosterwijk C, Nieuwenhuis MG et al. (1999) Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42:427-434
11. Verchere CB, D'Alessio DA, Palmiter RD et al. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492-3496
12. Bales KR, Verina T, Dodel RC et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17:263-264
13. Irizarry MC, Cheung BS, Rebeck GW, Paul SM, Bales KR, Hyman BT (2000) Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol (Berl) 100:451-458
14. Weisgraber KH, Mahley RW (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 10:1485-1494
15. Schmechel DE, Saunders AM, Strittmatter WJ et al. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653
16. Charge SB, Esiri MM, Bethune CA, Hansen BC, Clark A (1996) Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. J Pathol 179:443-447
17. Zhang SH, Reddick RL, Piedrahita JA, Maeda N (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468-471
18. Wang F, Hull RL, Vidal J, Cnop M, Kahn SE (2001) Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514-2520
19. Andrikopoulos S, Verchere CB, Terauchi Y, Kadowaki T, Kahn SE (2000) Beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes 49:2056-2062
20. Percy AJ, Trainor DA, Rittenhouse J, Phelps J, Koda JE (1996) Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 42:576-585
21. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC (2000) Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 20:1529-1535
22. Kahn SE, Andrikopoulos S, Verchere CB, Wang F, Hull RL, Vidal J (2000) Oophorectomy promotes islet amyloid formation in a transgenic mouse model of Type II diabetes. Diabetologia 43:1309-1312
23. Plump AS, Smith JD, Hayek T et al. (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353
24. Park K, Verchere CB (2001) Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. Implications for islet amyloid formation. J Biol Chem 276:16611-16616
25. Westermark P (1998) The pathogenesis of amyloidosis: understanding general principles. Am J Pathol 152:1125-1127
26. Bales KR, Verina T, Cummins DJ et al. (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96:15233-15238
27. Corder EH, Saunders AM, Risch NJ et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180-184
28. MacArthur DL, de Koning EJ, Verbeek JS, Morris JF, Clark A (1999) Amyloid fibril formation is progressive and correlates with beta-cell secretion in transgenic mouse isolated islets. Diabetologia 42:1219-1227
29. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45:1092-1096
30. Prince M, Lovestone S, Cervilla J et al. (2000) The association between APOE and dementia does not seem to be mediated by vascular factors. Neurology 54:397-402
31. Bodovitz S, Klein WL (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271:4436-4440
32. Wagner JD, Cline JM, Shadoan MK, Bullock BC, Rankin SE, Cefalu WT (2001) Naturally occurring and experimental diabetes in cynomolgus monkeys: a comparison of carbohydrate and lipid metabolism and islet pathology. Toxicol Pathol 29:142-148
33. Macfarlane WM, Campbell SC, Elrick LJ et al. (2000) Glucose regulates islet amyloid polypeptide gene transcription in a PDX-1 and calcium-dependent manner. J Biol Chem 275:15330-15335
34. Koning EJ de, Morris ER, Hofhuis FM et al. (1994) Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 91:8467-8471
35. Eto M, Watanabe K, Makino I, Ishii K (1991) Apolipoprotein E allele frequencies in non-insulin-dependent diabetes mellitus with hypertriglyceridemia (type IIb, III, IV, and V hyperlipoproteinemia). Metabolism 40:776-780
36. Inamdar PA, Kelkar SM, Devasagayam TP, Bapat MM (2000) Apolipoprotein E polymorphism in non-insulin-dependent diabetics of Mumbai, India and its effect on plasma lipids and lipoproteins. Diabetes Res Clin Pract 47:217-223
37. Lin CT, Xu YF, Wu JY, Chan L (1986) Immunoreactive apolipoprotein E is a widely distributed cellular protein. Immunohistochemical localization of apolipoprotein E in baboon tissues. J Clin Invest 78:947-958
38. Nakamura S, Kiatipattanasakul W, Nakayama H et al. (1996) Immunohistochemical study on the deposition of apolipoprotein E in cerebral and islet amyloidoses in cynomolgus monkeys (Macaca fascicularis). Exp Anim 45:199-203
39. Kida E, Choi-Miura NH, Wisniewski KE (1995) Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. Brain Res 685:211-216
40. Wisniewski KE, Ghiso J, Frangione B (1997) Biology of A beta amyloid in Alzheimer's disease. Neurobiol Dis 4:328
41. Boyles JK, Zoellner CD, Anderson LJ et al. (1989) A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 83:1015-1031
42. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC (2001) Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol 158:1173-1177
43. Kisilevsky R, Fraser PE (1997) A beta amyloidogenesis: unique, or variation on a systemic theme? Crit Rev Biochem Mol Biol 32:361-404